COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00657644
Recruitment Status : Completed
First Posted : April 14, 2008
Last Update Posted : December 25, 2014
Information provided by (Responsible Party):

Brief Summary:
To find out more information on how effective and safe vardenafil is at treating impotence in men living in Russia.

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Drug: Levitra (Vardenafil, BAY38-9456) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 130 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Multi-centre Non Randomised Study of Efficacy and Safety of Vardenafil (BAY 38-9456; SB-782528) Administered in Flexible-dose Regimen in Males With Erectile Dysfunction of Broad Aetiology.
Study Start Date : August 2003
Actual Primary Completion Date : March 2004
Actual Study Completion Date : March 2004

Arm Intervention/treatment
Experimental: Arm 1 Drug: Levitra (Vardenafil, BAY38-9456)
4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks

Primary Outcome Measures :
  1. Erectile Function (EF) domain score [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Erectile Function (EF) domain score [ Time Frame: Week 4, 8 and 12 Last Observation Carried Forward (LOCF) ]
  2. Change from baseline of Erectile Function domain score [ Time Frame: Week 4, 8 and 12 Last Observation Carried Forward (LOCF) ]
  3. IIEF domain scores [ Time Frame: Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF) ]
  4. Patient Diary Questions [ Time Frame: Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF) ]
  5. Global Assessment Question (GAQ) [ Time Frame: Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF) ]
  6. Premature termination, adverse events, laboratory abnormalities and concomitant medication usage [ Time Frame: Week 4, 8 and 12 ]
  7. Measurements and changes from baseline in vital signs, ECG cardiac cycle measurements and ECG heart rate [ Time Frame: Week 12 ]
  8. Haematology, Clinical Chemistry, Urinalysis [ Time Frame: Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males with ED according to the NIH definition (the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance) for at least 3 months.
  • Heterosexual relationship
  • Age range: 18 years and older
  • Documented written Informed Consent
  • The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary "Was sexual activity initiated with the intention of intercourse?") on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"] "Were you able to achieve at least partial erection (some enlargement of the penis)?", "Were you able to insert your penis in your partner's vagina?" and "Did your erection last long enough for you to have successful intercourse?".

Exclusion Criteria:

  • Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
  • Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) that in the opinion of the Investigator would significantly impair erectile function
  • Primary hypoactive sexual desire
  • Spinal cord injury
  • History of surgical prostatectomy (excluding TURP).
  • Retinitis pigmentosa
  • History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C.
  • History of positive test for HIV.9. Severe chronic or acute liver disease, history of moderate or severe hepatic impairment.
  • Clinically significant chronic hematological disease, which may lead to priapism such as sickle cell anemia and leukemia.
  • Bleeding disorder.
  • Significant active peptic ulceration.
  • Unstable angina pectoris
  • History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
  • Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate > 100 bpm).
  • Resting hypotension (a resting systolic blood pressure of < 90 mm Hg) or hypertension (a resting systolic blood pressure > 170 mm Hg or a resting diastolic blood pressure > 110 mm Hg)
  • NYHA Class III and IV heart failure
  • Symptomatic postural hypotension within 6 months of visit 1.
  • History of malignancy within the past 5 years (other than squamous or basal cell skin cancer).

Concomitant Medication:

  • Subjects who are taking nitrates or nitric oxide donors.
  • Subjects who are taking anti-androgens
  • Subjects who are taking androgens.
  • Subjects who take anticoagulants, except for antiplatelet agents.
  • Subjects who have received any investigational drug (including placebo) within 30 days of visit 1.6. Use of any treatment for ED within the 7 days of visit 1 or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
  • Subjects who are taking the following potent inhibitors of cytochrome P- 450 3A4: HIV protease inhibitors such as ritonavir or indinavir, the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
  • Subjects who are taking alpha-blockers.

Abnormal Laboratory Values:

  • Subjects who have a serum total testosterone level greater than 25% below the lower limit of normal according to the range of the testing laboratory
  • Subjects with a serum creatinine >3.0 mg/dl
  • Elevation of AST and/or ALT >3X the ULN.
  • Diabetic subjects with an HbA1c >12%.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00657644

Layout table for location information
Russian Federation
Moscow, Russian Federation, 105425
Moscow, Russian Federation, 117198
Moscow, Russian Federation, 117837
Moscow, Russian Federation, 117997
Moscow, Russian Federation, 123367
Moscow, Russian Federation, 125101
Moscow, Russian Federation, 127206
St Petersburg, Russian Federation, 198013
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00657644    
Other Study ID Numbers: 11182
First Posted: April 14, 2008    Key Record Dates
Last Update Posted: December 25, 2014
Last Verified: December 2014
Keywords provided by Bayer:
Erectile Dysfunction
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Vardenafil Dihydrochloride
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents